Inozyme Pharma (INZY) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Top-rated Biotechs With Negative Enterprise Values
Seeking AlphaMar 1 14:28 ET
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewswireFeb 24 08:30 ET
Express News | Inozyme Pharma To Present Interim Data For INZ-701 At CHOP Cardiology 2025
BenzingaFeb 21 08:32 ET
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children With ENPP1 Deficiency at CHOP Cardiology 2025
GlobeNewswireFeb 21 08:30 ET
Express News | Inozyme Pharma Shares Are Trading Lower After Multiple Firms Cut Their Respective Price Targets on the Stock
BenzingaJan 13 11:50 ET
Express News | Piper Sandler Maintains Overweight on Inozyme Pharma, Lowers Price Target to $30
BenzingaJan 13 10:25 ET

Comments

Jaguar8

Jan 10 07:06

NEWS

$Inozyme Pharma (INZY.US)$
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
5 minutes ago, 5:00 AM PST
Via GlobeNewswire
INZY
Share
- Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, including survival, heart function, and stabilization or reduction in ectopic calcification and hypophosphatemia, with no radiographi...

1

Jaguar8

Dec 15, 2024 20:58

🔶December 2024 Upcoming Catalysts. Save it. In alphabetical order

$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...

28

9

7

Jaguar8

Oct 24, 2024 12:15

NEWS

$Inozyme Pharma (INZY.US)$
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
Inozyme Pharma (INZY) announced positive interim data from its Phase 1 SEAPORT 1 trial of INZ-701 in patients with end-stage kidney disease (ESKD) undergoing hemodialysis. The trial demonstrated that INZ-701 significantly increased plasma pyrophosphate (PPi) levels in patients, with levels rising into the normal range by week 3 of the four-week dosing schedule. The drug was well-...

Jaguar8

Jul 25, 2024 07:31

NEWS

$Inozyme Pharma (INZY.US)$
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
Inozyme Pharma (Nasdaq: INZY) has published preclinical data in the journal Cells, supporting the potential of INZ-701, their lead ENPP1 enzyme replacement therapy (ERT) candidate, to treat a broad range of rare diseases affecting bone health and blood vessel function. The study demonstrates IN...

Jaguar8

May 23, 2024 07:33

$Inozyme Pharma (INZY.US)$
NEWS
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
Inozyme Pharma (Nasdaq: INZY) announced that it will present topline data from its Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency at two upcoming medical conferences. The presentations will occur at the European Calcified Tissue Society Congress (ECTS)...

INZY Inozyme Pharma

Trade Overview

Capital Trend

News

Comments

Trending Stocks